OncoMatch/Clinical Trials/NCT07102381
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Is NCT07102381 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for her2-positive breast cancer.
Treatment: Zanidatamab · Paclitaxel · Docetaxel · Carboplatin · Trastuzumab · Pertuzumab — The purpose of this study is to see if zanidatamab is safe and effective, when combined with chemotherapy, in treating people who has Human Epidermal Growth Factor Receptor 2 (HER2)-positive, early-stage breast cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Breast Carcinoma
Biomarker criteria
Required: HER2 (ERBB2) overexpression
Has histologically confirmed HER2-positive breast cancer
Disease stage
Required: Stage II, III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: surgery for invasive breast cancer
Was treated with surgery ... for invasive breast cancer
Cannot have received: chemotherapy for invasive breast cancer
Was treated with ... chemotherapy ... for invasive breast cancer
Cannot have received: anti-HER2 therapy
Was treated with ... anti-HER2 therapy ... for invasive breast cancer
Cannot have received: radiation therapy for invasive breast cancer
Was treated with ... radiation therapy ... for invasive breast cancer
Cannot have received: endocrine therapy for invasive breast cancer
Was treated with ... endocrine therapy ... for invasive breast cancer
Cannot have received: experimental therapy for invasive breast cancer
Was treated with ... experimental therapy ... for invasive breast cancer
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
lvef ≥ 50% as determined by either echo or muga obtained within 6 weeks prior to randomization
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Oncology Institute · Long Beach, California
- Accellacare of McFarland · Ames, Iowa
- LSU Health Sciences Center · Shreveport, Louisiana
- New England Cancer Specialists · Scarborough, Maine
- Maryland Oncology Hematology · Laurel, Maryland
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07102381 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages